Modus Therapeutics Holding AB (MODTX.ST)
Modus Therapeutics Holding AB operates in the Biotechnology industry of the Healthcare sector, headquartered in Stockholm, AB, SE. The stock last traded at $0.39, down 0.51% on the session, giving a market capitalisation of $35.3M. Its beta of 0.38 implies it has historically moved less than the broad market.
Modus Therapeutics Holding AB (publ), a biotechnology company, develops a treatment for sepsis and septic shock in Sweden. It develops Sevuparin, a lipopolysaccharide in Phase IIa trial to treat patients with sepsis, septic shock, anemia associated with chronic kidney disease, endotoxemia, severe malaria, and other diseases involving severe systemic inflammation. Modus Therapeutics Holding AB (publ) was founded in 2011 and is headquartered in Stockholm, Sweden.
Modus Therapeutics Holding AB is most often compared with the following Healthcare names: